Closing the Healthcare Gaps in the Management of Moderate-to-Severe Atopic Dermatitis (AD) With Biologics

0.75 CME
45 MINS
$0 FEE
SAVE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Closing the Healthcare Gaps in the Management of Moderate-to-Severe Atopic Dermatitis (AD) With Biologics

Overview

Provider Statement

This continuing education activity is provided by CMEsquared.

Support Statement

This activity is supported by an educational grant from Lilly.

Intended Audience

This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Discuss the burden of disease in patients with moderate-to-severe AD
  • Describe how biologics target the disease pathway for AD
  • Review the clinical trial data for biologics to treat moderate-to-severe AD
  • Discuss the safety profile of biologics and how to manage adverse effects

Faculty

April Armstrong, MD, MPH
Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA

Peter Lio, MD
Clinical Assistant Professor of Dermatology Pediatrics 
Northwestern University Feinberg School of Medicine
Chicago, IL

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada and CMEsquared. The University of Nevada is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Nevada designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

CONFLICTS OF INTEREST/DISCLOSURES

In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer. 

Disclosures are as follows:

April W. Armstrong, MD, MPH
Grant/Research Support: BMS, Leo, UCB, Lilly, Dermavant, Dermira, Pfizer, AbbVie, ASLAN, BI, EPI, Incyte, Janssen
Consultant: Lilly, Novartis, Ortho, SUN, Dermavant, Dermira, Sanofi Regeneron, Pfizer, Parexel

Peter A. Lio, MD
has disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.

The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.

The University of Nevada discloses that all relevant conflicts have been satisfactorily mitigated.